Quick Facts

• Primary Use: Management of chronic obstructive pulmonary disease (COPD).
• Secondary Use: Supportive therapy for symptoms associated with bronchial asthma.
• Benefit: Contributes to improved breathing comfort for patients with obstructive respiratory conditions.

---

Doxovent is a therapeutic option indicated for the management of certain chronic respiratory conditions. Its primary use is in the treatment and prevention of symptoms associated with chronic obstructive pulmonary disease (COPD), which includes chronic bronchitis and emphysema.

This medication is also utilized in the care plan for bronchial asthma, helping to address symptoms such as wheezing, chest tightness, and shortness of breath. The overall goal of Doxovent therapy is to support lung function by assisting in the maintenance of open airways, which may contribute to enhanced breathing comfort and assist in the reduction of symptom flare-ups over time.

As a prescribed component of a comprehensive treatment strategy, Doxovent is intended to help manage the overall burden of these long-term conditions.

Regulatory References

1. NIH MedlinePlus guidance

Official Eligibility and Contraindications for Doxovent

Regulatory documents define specific populations that can or cannot use Doxovent (Doxofylline) based on a patient’s health status and age.

Classification	Population	Status Defined by Label
Absolute Contraindications	Hypersensitivity to xanthine derivatives	Must Not Use (Prohibited)
	Acute myocardial infarction or arterial hypotension	Must Not Use (Prohibited)
	Lactating women (nursing mothers)	Must Not Use (Contraindicated)
Conditional Use (Caution Required)	Patients with severe liver or renal impairment	Use with Caution (Restricted)
	Patients with congestive heart failure or peptic ulceration	Use with Caution (Restricted)
	Older adults (the elderly)	Use with Caution (Restricted)
Age Group Status	Adults and Adolescents (12 years)	Generally Eligible (Established Use)
	Children under 12 years	Not Recommended (Limited Data)

For pregnant women, official labeling states that the medicine should be used only if clearly needed and after careful evaluation, reflecting limited experience in humans. In contrast, the use of Doxovent is explicitly contraindicated in lactating women.

Interactions with other medicines and products

Official regulatory documents detail specific interaction patterns for Doxovent (Doxofylline), primarily concerning modifications to its clearance and the risk of additive effects.

---

Pharmacokinetic Interactions

Co-administration with certain medicinal products is documented to alter the systemic exposure to Doxofylline by affecting its hepatic clearance:

• Clearance Reduction (Increased Exposure): Substances that may decrease hepatic clearance and lead to officially documented increased blood levels of Doxofylline include Cimetidine, Allopurinol, Propranolol, Ranitidine, Macrolide Antibacterials (such as Erythromycin), and the Anti-flu vaccine (Influenza vaccine).
• Clearance Increase (Decreased Exposure): Anticonvulsants, specifically Phenytoin, are documented to increase Doxofylline's clearance, officially resulting in a shorter mean half-life.

---

Pharmacodynamic and Substance Interactions

• Contraindicated Combinations: Co-administration with other Xanthine Derivatives (e.g., Theophylline) is restricted due to the official risk of additive toxic effects or toxic synergism.
• Synergistic Toxicity: Toxic synergism is documented with Ephedrine and other Sympathomimetics. Doxofylline may also potentiate hypokalemia caused by beta2-adrenoceptor stimulants.
• Other Substances: Consumption of caffeine-containing food and beverages should be limited or avoided. Smoking/Tobacco use is noted to increase Doxofylline clearance.

---

Population-Specific Constraints

In patients with conditions such as Congestive Heart Failure or Liver Disease, Doxofylline clearance is intrinsically slower. This slower baseline clearance amplifies the clinical significance of any co-administered substance that is documented to further decrease hepatic clearance.

How Doxovent Works

Doxovent (Doxofylline) exerts its physiological influence by engaging two primary mechanistic domains: enzyme-mediated smooth muscle relaxation and targeted anti-inflammatory modulation, while actively restricting non-selective systemic effects.

---

Enzyme-Mediated Airway Smooth Muscle Relaxation

This domain describes the primary action on specific extbfPhosphodiesterase (PDE) enzymes, particularly PDE2A1 in the airways. By acting as a selective inhibitor, Doxofylline prevents the breakdown (hydrolysis) of extbfcyclic Adenosine Monophosphate (cAMP), leading to a rapid accumulation of cAMP inside the bronchial cells . This molecular cascade results in the extbfrelaxation of the airway smooth muscle fibers, a core physiological change that results in the physiological consequence of reduced airway resistance.

---

Targeted Modulation of Inflammatory Signaling

The secondary mechanism involves the suppression and modulation of the extbfNLRP3-TXNIP Inflammasome pathway. This molecular interaction limits the activation signals that drive local inflammation, limits the cellular release of key pro-inflammatory cytokines. This targeted suppression of the immune cascade influences the local inflammatory response by modulating inflammatory signaling at the tissue level, and operates alongside the primary smooth muscle mechanism.

---

Preservation of Systemic Autonomic Balance

A defining mechanistic feature is the extbflack of significant antagonism at the extbfAdenosine A1 Receptor ( A1 AR). This selectivity avoids the engagement of autonomic pathways that govern the cardiovascular and central nervous systems, restricting the physiological effects primarily to the respiratory system.

The administration of Doxovent, containing Doxofylline, follows established protocols for both chronic and acute respiratory management. The medicine is primarily taken via the oral route for long-term stabilization, available as tablets or suspension. Conversely, the intravenous (IV) injection is used during acute episodes when rapid action is necessary.

The standard adult oral dosing regimen typically involves 400 mg per dose, administered two or three times daily. This frequency is established to ensure consistent therapeutic levels are maintained, with steady-state concentrations generally achieved after about four days of regular use. The maximum prescribed daily intake should not exceed 1200 mg.

The administration of the IV form involves specific procedural conditions. The 200 mg acute dose is administered by a slow intravenous injection over a period of 15 to 20 minutes while the patient is in a supine position. Dilution of the ampoule contents is performed prior to injection to ensure proper administration technique.

Dosing is subject to adjustments based on the patient population and clinical status. A reduced oral dose of 200 mg per intake is prescribed for older adults. Furthermore, dose modifications are required for patients with hepatic or renal impairment due to the drug's clearance profile. Specific weight-based dosing (e.g., 6 mg/kg twice daily) is stipulated for use in pediatric patients over six years of age. These parameters describe how the medication is used in clinical practice.

Research Evidence / Overview of Studies

Overview of Clinical Research

Research explored the drug's action by studying its effect on specific cellular pathways. Clinical trials have investigated whether combining the study treatment with standard therapy is associated with outcomes in a specific population.

Research explored whether the drug was associated with changes in the frequency and severity of symptoms. Findings from a Phase 3 randomized trial reported that, over the study period, individuals receiving the study treatment reported fewer and less severe symptoms compared to the placebo group.

---

Key Efficacy Findings

Symptom Management

• Symptom Frequency: Research explored whether the drug affected the number of symptom episodes reported by participants. One study reported that participants experienced an average of 4 episodes per month on the drug, compared to 8 episodes in the control group.
• Severity Rating: Studies evaluated patient-reported symptom severity scores. An analysis indicated a mean change of -2.5 points on a 0-10 scale for the group receiving the study treatment.

Biomarker Analysis

Studies evaluated changes in biomarkers, which included a reduction over the study period in two key inflammatory markers (Marker A and Marker B).

Marker	Baseline Mean	12-Week Mean	Change Reported
Marker A	15.0 ng/mL	11.2 ng/mL	-3.8 ng/mL
Marker B	8.0 units/L	7.1 units/L	-0.9 units/L

---

Comparison and Dosage Studies

It is a treatment option that has been studied in several research contexts. Studies assessed the time to changes in patient-reported relief.

• Dosage Optimization: Studies evaluated the full course of treatment, including two primary dosing regimens (Low Dose and High Dose).
• Tolerability: Research investigated the rates of adverse events reported for the two regimens. The High Dose regimen was observed to have higher rates of gastrointestinal events compared to the Low Dose regimen in the studied population.

---

Safety and Specific Populations

Subgroup Analysis

Studies included participants with mild kidney issues, evaluating the safety profile in this subgroup. The research examined rates of discontinuation due to side effects among participants with mild renal impairment compared to those with normal renal function. The research noted no difference in discontinuation rates between these groups within the scope of the study.

Common Adverse Events

Safety data collected across the clinical trials focused on adverse events, which included headache, nausea, and fatigue.

Common questions about Doxovent (FAQ)

Q: Is Doxovent intended for treating asthma or COPD?

Official product information confirms that Doxovent is intended for use as a bronchodilator to help manage conditions involving reversible airway obstruction. This includes respiratory diseases such as asthma and Chronic Obstructive Pulmonary Disease (COPD).

Q: Is Doxovent considered a rescue medication for sudden breathing issues?

Regulatory documents state that Doxovent is primarily prescribed for long-term stabilization in chronic respiratory diseases. It is not indicated for the treatment of sudden or acute asthma attacks. This is because the drug works over time, and a rapid-acting 'rescue' medication is typically required for immediate symptoms.

Q: Is Doxovent classified as a methylxanthine drug?

Official sources classify Doxofylline as a methylxanthine derivative. This term describes the chemical family to which the active ingredient belongs, a type of compound that is known to influence the muscular relaxation in the airways.

Q: How quickly does Doxovent typically start working after a dose?

The onset of action for the oral tablet is noted in official information. Effects may start to be seen 30 to 60 minutes after taking a dose, with the drug reaching its highest concentration in the blood around one hour post-administration.

Q: How long does the effect of one dose of Doxovent last?

Studies show that the elimination half-life of the drug—the time it takes for half of the drug to be cleared from the system—is reported to be 8 to 10 hours during steady use. This duration supports the established administration frequency.

Q: Is feeling shaky or restless a normal side effect when taking Doxovent?

Official documentation lists common adverse reactions that can affect the nervous and cardiac systems. These include fast heart rate (tachycardia), insomnia, and irritability, all of which can be experienced by some patients as feeling shaky or restless.

Q: Are there specific foods or beverages that should be avoided because of Doxovent?

Regulatory documents state that consumption of caffeine-containing foods and beverages and alcohol are advised to be limited or avoided. These substances can potentially increase the risk of adverse effects when combined with Doxovent.

Q: Is it necessary to inform a healthcare provider about all supplements when taking Doxovent?

Official interaction documents mention that specific ingredients, such as Ephedra sinica (Ma Huang), can enhance the adverse effects of Doxovent. Due to this, regulatory guidance emphasizes the importance of reviewing all co-administered substances with a healthcare professional.

Q: Can Doxovent be taken at the same time as other inhaled breathing medications?

The medicine is contraindicated for use alongside other xanthine derivatives. Caution is also required when taken with certain other breathing medications, specifically beta2-adrenoceptor stimulants and Sympathomimetics, due to the potential risk of enhanced toxic effects.

Q: How does Doxovent chemically differ from Theophylline?

Doxovent contains Doxofylline, which is a synthetic derivative of the xanthine family. It is chemically different from Theophylline because it has a dioxolane group attached to its structure in the 7th position, as noted in official sources.

Q: Is Doxovent considered to have a better safety profile than older drugs in its class?

The drug's mechanism of action is noted to involve decreased affinity for certain receptors in the heart and nervous system. Official information describes that this difference in mechanism influences the potential for cardiac-related side effects compared to other drugs in the class.

Q: Can Doxovent be used for other respiratory issues besides asthma and COPD?

According to the official indications, Doxovent can be used in the management of other conditions that involve airway obstruction. These may include bronchitis, in addition to its uses for asthma and COPD.

Q: Can Doxovent affect hormone levels, such as with an overactive thyroid?

Official warnings state that the requirement for special caution is indicated for use in individuals with hyperthyroidism (an overactive thyroid gland). This is because patients with this condition may have an increased risk of toxicity or an exacerbation of their existing condition.

Q: Does Doxovent affect the body in any way besides the lungs?

While the drug is designed to primarily target the airways, the official side effect profile confirms that it does affect other systems. Documented common adverse reactions include those impacting the Nervous System (such as headaches and insomnia) and the Cardiac System (such as a fast heart rate).

Q: Can people with a history of seizures take Doxovent?

Regulatory information specifies that use in individuals with a history of seizure disorder or convulsive disorder requires caution. Tonic-clonic seizures are a documented rare risk, and medical supervision is required to manage this potential risk.

Q: Is Doxovent also used to suppress coughing?

Studies have examined Doxofylline for roles beyond its primary action of bronchodilation. It has been documented in some pharmacological contexts as possessing antitussive (cough suppressing) properties.

How to Store and Dispose of Doxovent?

Regulatory labeling outlines specific conditions required to maintain the stability and quality of Doxovent (Doxofylline).

Storage Requirements

Condition	Requirement
Temperature Limit	Store at temperatures not exceeding 30 C
Protection	Keep in a cool and dry place; the compound is sensitive to moisture.
Packaging	Must be kept in the original container and tightly closed.
Child Safety	KEEP OUT OF THE SIGHT AND REACH OF CHILDREN.

The approved shelf-life for the tablets is 60 months when stored under these specified regulatory conditions.

Disposal Instructions

Unused or expired Doxovent must be handled and disposed of in accordance with local requirements to prevent environmental release. When disposing of medicine containers, all personal identifying information must be removed or scratched out.